As shown in Figure 2C, the proliferation inhibition of CFSE-labeled CD4+CD25− T cells was greater using ICOS+ Tregs than ICOS− Tregs from the same patients with AML. This evidence concerns the gene CD4 and acute myeloid leukemia.